Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer

被引：0
作者：
Yasmin M. Attia
Salama A. Salama
Samia A. Shouman
Cristina Ivan
Abdelrahman M. Elsayed
Paola Amero
Cristian Rodriguez-Aguayo
Gabriel Lopez-Berestein
机构：
[1] Cairo University,Pharmacology and Experimental Therapeutics Unit, Cancer Biology Department, National Cancer Institute
[2] Al-Azhar University,Pharmacology and Toxicology Department, Faculty of Pharmacy
[3] The University of Texas MD Anderson Cancer Center,Department of Experimental Therapeutics
[4] The University of Texas MD Anderson Cancer Center,Center for RNA Interference and Non
[5] The University of Texas MD Anderson Cancer Center,Coding RNA
来源：
Pharmacological Reports | 2022年 / 74卷
关键词：
Breast cancer; Cancer stem cells; Tamoxifen; Cyclin-dependent kinase; SOX2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：366 / 378
页数：12
相关论文
共 50 条
  • [1] Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER plus breast cancer
    Attia, Yasmin M.
    Salama, Salama A.
    Shouman, Samia A.
    Ivan, Cristina
    Elsayed, Abdelrahman M.
    Amero, Paola
    Rodriguez-Aguayo, Cristian
    Lopez-Berestein, Gabriel
    PHARMACOLOGICAL REPORTS, 2022, 74 (02) : 366 - 378
  • [2] Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
    Attia, Yasmin M.
    Shouman, Samia A.
    Salama, Salama A.
    Ivan, Cristina
    Elsayed, Abdelrahman M.
    Amero, Paola
    Rodriguez-Aguayo, Cristian
    Lopez-Berestein, Gabriel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
  • [3] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [4] Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36
    Shen, Yingying
    Zhong, Jing
    Liu, Jianghua
    Liu, Kehuang
    Zhao, Jun
    Xu, Ting
    Zeng, Ting
    Li, Zhimei
    Chen, Yajun
    Ding, Wenjun
    Wen, Gebo
    Zu, Xuyu
    Cao, Renxian
    ONCOLOGY REPORTS, 2018, 39 (06) : 2604 - 2612
  • [5] Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+Breast Cancer
    Menendez, Javier A.
    Papadimitropoulou, Adriana
    Vander Steen, Travis
    Cuyas, Elisabet
    Oza-Gajera, Bharvi P.
    Verdura, Sara
    Espinoza, Ingrid
    Vellon, Luciano
    Mehmi, Inderjit
    Lupu, Ruth
    CANCERS, 2021, 13 (05) : 1 - 19
  • [6] CDK7 in breast cancer: mechanisms of action and therapeutic potential
    Gong, Ying
    Li, Huiping
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [7] Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer
    Rahem, Sarra M.
    Epsi, Nusrat J.
    Coffman, Frederick D.
    Mitrofanova, Antonina
    EBIOMEDICINE, 2020, 61
  • [8] Quercetin reverses tamoxifen resistance in breast cancer cells
    Wang, Hongxian
    Tao, Linyu
    Qi, Ke
    Zhang, Haoyun
    Feng, Duo
    Wei, Wenjun
    Kong, Heng
    Chen, Tianwen
    Lin, Qiusheng
    JOURNAL OF BUON, 2015, 20 (03): : 707 - 713
  • [9] Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER plus ve Breast Cancer
    Tsoi, Ho
    You, Chan-Ping
    Leung, Man-Hong
    Man, Ellen P. S.
    Khoo, Ui-Soon
    CANCERS, 2022, 14 (05)
  • [10] Glucose Metabolic Reprogramming of ER+ Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Mannelli, Michele
    Parri, Matteo
    Comito, Giuseppina
    Ippolito, Luigi
    Giannoni, Elisa
    Bonechi, Martina
    Benelli, Matteo
    Migliaccio, Ilenia
    Malorni, Luca
    Chiarugi, Paola
    Morandi, Andrea
    CELLS, 2020, 9 (03)
12345